ArticleFrontiers in oncology2025
Global burden of colorectal cancer from 1990 to 2021: a systematic analysis from the Global Burden of Disease Study 2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Fecal Immunochemical Test and Multitarget Stool DNA Testing for Colorectal Cancer Screening in Real-World Practice: A Literature Review.Journal of clinical medicine · 2026Review
- The Interaction Between Iron and Selenium Affects Ferroptosis in Colorectal Cancer.International journal of molecular sciences · 2026Review
- Screening, Prognostic, and Predictive Molecular Tools for Colorectal Cancer: Recent Advances in the Classical Background.International journal of molecular sciences · 2026Review
- Global, regional and national burden of colorectal cancer attributable to low-fiber diet from 1990 to 2021: a systematic analysis of the global burden of disease study 2021.Frontiers in nutrition · 2026Article
- The gut microbiota-enteric nervous system axis: from bidirectional programming to precision therapeutics in digestive diseases.Frontiers in cellular and infection microbiology · 2026Review
- Epidemiological trends and future burden of skin and subcutaneous diseases in China: insights from the global burden of disease study 2021.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC), currently the second leading cause of cancer-related mortality worldwide, poses a significant burden on public health. This study systematically analyzes the temporal trends in CRC disease burden based on Global Burden of Disease (GBD) data from 1990 to 2021, aiming to provide robust evidence for epidemiological research, disease prevention, and the formulation of public health policies. Methods: This study analyzed CRC incidence, mortality, and disability-adjusted life years (DALYs) using GBD1990-2021 data. Temporal trends were evaluated via estimated annual percentage changes (EAPC), with Pearson correlation assessing Socio-demographic Index (SDI) associations. Projections of global CRC epidemiology through 2035 were developed to inform public health strategies. Results: In 2021, global CRC accounted for 2,194,143 incident cases, 1,044,072 deaths, and 24,401,100 DALYs. CRC remains a major public health challenge worldwide. From 1990 to 2021, age-standardized incidence rates (ASIR) increased (EAPC = 0.15, 95% CI: 0.12-0.19), while mortality (EAPC=-0.81, -0.84 to -0.77) and DALY rates (EAPC=-0.83, -0.87 to -0.80) declined significantly. Notable socioeconomic gradients were observed across the spectrum of regions. Geographic disparities were prominent: high-SDI regions had the highest ASIR (40.525, 37.445-42.447 per 100,000), whereas high-middle-SDI regions showed peak mortality (15.709, 14.144-17.25) and DALY rates (338.225, 316.751-354.913). Males and individuals aged >85 years experienced disproportionate burden increases. By 2035, the global burden of CRC is projected to maintain its current upward trajectory. Conclusions: Globally, CRC's ASIR has gradually increased, while age-standardized death rate (ASDR) and DALY rates have declined significantly, reflecting an overall reduction in disease burden. Regions with higher SDI, male predominance, and aging populations contribute most to rising CRC cases. Despite progress in mortality reduction, CRC prevention and control will continue to pose significant public health challenges in the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.